Dapagliflozin Propanediol

Generic Details

Generic Name

Dapagliflozin Propanediol

Other Names

  • Farxiga

Drug Class

  • Sodium-glucose co-transporter 2 (SGLT2) inhibitors

Chemical Formula

C21H25ClO6

Molecular Weight

408.87 g/mol

Mechanism of Action

  • Inhibits SGLT2 in the renal proximal tubules, reducing reabsorption of glucose and increasing urinary glucose excretion

Indications

  • Type 2 diabetes mellitus

Common Dosage Forms

  • Tablet

Typical Dosage

  • 5-10 mg orally once daily

Pediatric Dosage

    Geriatric Dosage

      Side Effects

      • Genital mycotic infections
      • Urinary tract infections
      • Increased urination
      • Hypotension
      • Hypoglycemia

      Contraindications

      • Severe renal impairment (eGFR <30 mL/min/1.73 m²)
      • Hypersensitivity to dapagliflozin

      Pregnancy Category

      • Category C

      Lactation Safety

      • Not recommended during breastfeeding

      Drug Interactions

      • Diuretics
      • Insulin
      • ACE Inhibitors

      Overdose Symptoms

      • Dehydration
      • Hypotension
      • Hypovolemia

      Antidote for Overdose

      • Supportive care and monitoring

      Storage Conditions

      • Store at room temperature away from moisture and heat

      Pharmacokinetics

      • Absorption: Rapidly absorbed after oral administration
      • Distribution: Protein binding: 91%
      • Metabolism: Primarily metabolized by UGT1A9 and UGT2B7 in the liver
      • Excretion: 70% via urine, 21% via feces

      Precautions

      • Monitor renal function regularly
      • Discontinue if acute kidney injury occurs

      Warnings

      • Increased risk of euglycemic diabetic ketoacidosis
      • Hypotension risk in elderly

      Others

      • May reduce the risk of cardiovascular death or hospitalization for heart failure in diabetic patients with underlying heart disease